Tenax Granted Notice of Allowance for U.S. Patent : comparem

Patent is expected to provide additional intellectual property protection until 2040 Prevalence estimates indicate that PH-HFpEF affects over 1,500,000...

Related Keywords

Finland , United States , Ukraine , American , John Mullaly , Chris Giordano , American Heart Association Science Advisory , Lifesci Advisors , Nasdaq , Orion Corporation , Trademark Office , Nasdaq Stock Market , Tenax Therapeutics Inc , United States Patent , Tenax Therapeutic , Tenax Therapeutic Chief Executive Officer , Tenax Therapeutics , Stuart Rich , Chief Medical Officer , American Heart Association Science , Clinical Implications , Pulmonary Hypertension , Heart Failure With Preserved Ejection Fraction , Science Advisory From , American Heart Association , North American , Tenax Therapeutic Phase , Sci Advisors , Nasdaq Tenx ,